These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 23258740)

  • 21. A combination of AZD5363 and FH5363 induces lethal autophagy in transformed hepatocytes.
    Patra T; Meyer K; Ray RB; Ray R
    Cell Death Dis; 2020 Jul; 11(7):540. PubMed ID: 32681102
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
    Grünwald V; DeGraffenried L; Russel D; Friedrichs WE; Ray RB; Hidalgo M
    Cancer Res; 2002 Nov; 62(21):6141-5. PubMed ID: 12414639
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Co-treatment of LY294002 or MK-2206 with AZD5363 Attenuates AZD5363-induced Increase in the Level of Phosphorylated AKT.
    Choi AR; Kim JH; Woo YH; Cheon JH; Kim HS; Yoon S
    Anticancer Res; 2016 Nov; 36(11):5849-5858. PubMed ID: 27793908
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical pharmacology of AZD5363, an inhibitor of AKT: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background.
    Davies BR; Greenwood H; Dudley P; Crafter C; Yu DH; Zhang J; Li J; Gao B; Ji Q; Maynard J; Ricketts SA; Cross D; Cosulich S; Chresta CC; Page K; Yates J; Lane C; Watson R; Luke R; Ogilvie D; Pass M
    Mol Cancer Ther; 2012 Apr; 11(4):873-87. PubMed ID: 22294718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Combination treatment of prostate cancer with FGF receptor and AKT kinase inhibitors.
    Feng S; Shao L; Castro P; Coleman I; Nelson PS; Smith PD; Davies BR; Ittmann M
    Oncotarget; 2017 Jan; 8(4):6179-6192. PubMed ID: 28008155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
    McCubrey JA; Steelman LS; Abrams SL; Lee JT; Chang F; Bertrand FE; Navolanic PM; Terrian DM; Franklin RA; D'Assoro AB; Salisbury JL; Mazzarino MC; Stivala F; Libra M
    Adv Enzyme Regul; 2006; 46():249-79. PubMed ID: 16854453
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel PI3K inhibitor displays potent preclinical activity against an androgen-independent and PTEN-deficient prostate cancer model established from the cell line PC3.
    Shi M; Zhou X; Zhang Z; Wang M; Chen G; Han K; Cao B; Liu Z; Mao X
    Toxicol Lett; 2014 Aug; 228(3):133-9. PubMed ID: 24831963
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Icariside II on Human Prostate Cancer Cell Proliferation, Mobility, and Autophagy via PI3K-AKT-mTOR Signaling Pathway.
    Li S; Zhan Y; Xie Y; Wang Y; Liu Y
    Drug Des Devel Ther; 2020; 14():4169-4178. PubMed ID: 33116405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Down-modulation of Bcl-2 sensitizes PTEN-mutated prostate cancer cells to starvation and taxanes.
    Calastretti A; Gatti G; Quaresmini C; Bevilacqua A
    Prostate; 2014 Oct; 74(14):1411-22. PubMed ID: 25111376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype.
    Hong SW; Shin JS; Moon JH; Kim YS; Lee J; Choi EK; Ha SH; Lee DH; Chung HN; Kim JE; Kim KP; Hong YS; Lee JL; Lee WJ; Choi EK; Lee JS; Jin DH; Kim TW
    Apoptosis; 2014 May; 19(5):895-904. PubMed ID: 24652480
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells.
    Cao C; Subhawong T; Albert JM; Kim KW; Geng L; Sekhar KR; Gi YJ; Lu B
    Cancer Res; 2006 Oct; 66(20):10040-7. PubMed ID: 17047067
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts.
    Wu L; Birle DC; Tannock IF
    Cancer Res; 2005 Apr; 65(7):2825-31. PubMed ID: 15805283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antibody targeting of HER2/HER3 signaling overcomes heregulin-induced resistance to PI3K inhibition in prostate cancer.
    Poovassery JS; Kang JC; Kim D; Ober RJ; Ward ES
    Int J Cancer; 2015 Jul; 137(2):267-77. PubMed ID: 25471734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
    Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
    Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate cancer cells.
    Kim SH; Park EJ; Lee CR; Chun JN; Cho NH; Kim IG; Lee S; Kim TW; Park HH; So I; Jeon JH
    Int J Oncol; 2012 May; 40(5):1683-90. PubMed ID: 22200837
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
    Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
    Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of autophagy enhances apoptosis induced by the PI3K/AKT/mTor inhibitor NVP-BEZ235 in renal cell carcinoma cells.
    Li H; Jin X; Zhang Z; Xing Y; Kong X
    Cell Biochem Funct; 2013 Jul; 31(5):427-33. PubMed ID: 23086777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rottlerin induces autophagy and apoptosis in prostate cancer stem cells via PI3K/Akt/mTOR signaling pathway.
    Kumar D; Shankar S; Srivastava RK
    Cancer Lett; 2014 Feb; 343(2):179-89. PubMed ID: 24125861
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-1-6-heptadine-3,5-dione; C21H20O6] sensitizes human prostate cancer cells to tumor necrosis factor-related apoptosis-inducing ligand/Apo2L-induced apoptosis by suppressing nuclear factor-kappaB via inhibition of the prosurvival Akt signaling pathway.
    Deeb D; Jiang H; Gao X; Al-Holou S; Danyluk AL; Dulchavsky SA; Gautam SC
    J Pharmacol Exp Ther; 2007 May; 321(2):616-25. PubMed ID: 17289836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.